Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of suPAR in Doxorubicin Induced Cardiomyopathy in Breast Cancer Patients: Causative vs. Predictor

NCT03505164 is registered in ClinicalTrials.gov with Rush University Medical Center as lead sponsor.

NCT NCT03505164
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03505164 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of suPAR in Doxorubicin Induced Cardiomyopathy in Breast Cancer Patients: Causative vs. Predictor
Lead sponsor
Rush University Medical Center
Phase
Observational
Overall status
Completed
Start date
January 17, 2017
Completion date
July 6, 2020
Enrollment
42 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cardiomyopathies, secondary, doxorubicin adverse reaction